SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Shawarma and rubble: The paradox of Gaza’s post-war recovery

“Global LPs now assume Israeli founders can operate through geopolitical shocks, volatility, operational chaos, and even war”

Chinese fund: “The Chinese government has imposed a ban on any new investment in Israel”

Innovation or exhaustion? The human cost of tech’s AI reset

Buzz

Most popular

Daily

Weekly

1

Why Apple paid billions for a company with no revenue

2

Valued at $800 million after less than two years, Vega eyes the path blazed by Wiz

3

Google-Wiz deal expected to be cleared by EU following meeting with regulators, report says

4

Israeli startups raise over $1 billion in January, marking best opening month since 2022

5

From secret satellites to civilian services: Israel’s space industry reinvents itself

Merck

5 stories about Merck

Biolojic Design lands drug discovery collaboration with Merck potentially worth up to 346 million euros

03.06.24|Sophie Shulman

The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders.

ד״ר צחון בנטואיץ׳ מייסד משותף של קיוריס Quris AI

Pharma giant Merck expands collaboration with Quris-AI

28.09.23|Meir Orbach

This follows the successful initial collaboration, a preclinical study to assess Quris-AI’s ability to predict drug toxicity in comparison to traditional in vitro and in vivo approaches

מוסף שבועי 18.5.23 פרופסור גל מרקל

Israeli biotech phenom puts death knell on cancer

21.05.23|Roni Dori

At 44, Gal Markel is a biotech bulldozer. After a $95 million exit, the professor of immunology serves as the Deputy Director General of Beilinson Hospital and the Director of the Davidoff Cancer Center, and is also involved in five startups. Now he has raised around $33 million to establish the Samueli Institute, researching ways to help the immune system eradicate cancer cells

“Pharma companies need to capitalize on early-stage breakthrough innovation.”

Collaboration is key for pharmaceutical companies as they seek to make the drug development process more efficient and successful, says Larisa Amir, managing director of Merck’s R&D Center.

Larisa Amir appointed Managing Director of Merck R&D Center in Israel

Amir will be responsible for managing the center and will also focus on in-house innovation and external scouting for technologies and biotechnology capabilities in Israeli startups, academia, and hospitals